tradingkey.logo
tradingkey.logo
Pesquisar

Daxor Corp

DXR
Adicionar à lista de desejos
11.090USD
+0.740+7.15%
Horário de mercado ETCotações atrasadas em 15 min
56.11MValor de mercado
31.89P/L TTM

Mais detalhes de Daxor Corp Empresa

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Informações de Daxor Corp

Código da empresaDXR
Nome da EmpresaDaxor Corp
Data de listagemJul 25, 1983
CEOFeldschuh (Michael Richard)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 25
EndereçoSuite 7120
CidadeNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10118
Telefone12122440555
Sitehttps://www.daxor.com/
Código da empresaDXR
Data de listagemJul 25, 1983
CEOFeldschuh (Michael Richard)

Executivos da empresa Daxor Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
--
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
--
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
--
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
--
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--

Perguntas frequentes

Quem são os cinco principais acionistas de Daxor Corp?

Os cinco principais acionistas de Daxor Corp são: Mr. Michael Richard Feldschuh

Quantas instituições possuem ações da Daxor Corp (DXR)?

Em 2026Q1, 16 instituições possuíam ações da Daxor Corp, com valor de mercado aproximado de 120.43K, representando 2.07% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 11270.00.